CareDx Appoints Bryan Riggsbee to Its Board of Directors
March 11 2024 - 3:10PM
Business Wire
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a
leading precision medicine company focused on the discovery,
development, and commercialization of clinically differentiated,
high-value healthcare solutions for transplant patients and
caregivers — today announced that Bryan Riggsbee joins CareDx’s
Board of Directors, effective March 11, 2024.
“We're pleased to welcome Bryan to our Board,” said Michael
Goldberg, CareDx Board Chairperson. “His financial expertise,
operating background and deep understanding of revenue cycle
management in molecular diagnostics will allow him to make
meaningful contributions to our Board.”
Riggsbee previously served as Chief Financial Officer at Myriad
Genetics, where he made substantial contributions to the company's
growth strategy and business transformation. With a decade-long
tenure at Laboratory Corporation of America (LabCorp), Riggsbee has
demonstrated proven financial acumen. His background also includes
notable finance roles at General Electric Company. He began his
career in the audit division of KPMG and is a Certified Public
Accountant licensed in the state of North Carolina.
“I am thrilled to join the CareDx Board, an innovator and leader
in the field of organ transplantation,” said Riggsbee. “I look
forward to working with the company’s leadership team to advance
its mission of improving long-term outcomes by delivering
innovative solutions across the entire transplant patient
journey.”
Riggsbee joins the Board as Chair of the Audit and Finance
Committee, where he succeeds George Bickerstaff, who will continue
to serve on the Committee.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a
leading precision medicine solutions company focused on the
discovery, development, and commercialization of clinically
differentiated, high-value healthcare solutions for transplant
patients and caregivers. CareDx offers testing services, products,
and digital healthcare solutions along the pre- and post-transplant
patient journey and is the leading provider of genomics-based
information for transplant patients. For more information, please
visit: www.CareDx.com.
Forward-Looking Statements
This press release includes forward-looking statements related
to CareDx, Inc., including statements regarding the potential
benefits and results that may be achieved with the appointment of
Bryan Riggsbee to the Board. These forward-looking statements are
based upon information that is currently available to CareDx and
its current expectations, speak only as of the date hereof, and are
subject to risks and uncertainties that could cause actual results
to differ materially from those projected, including general
economic and market factors; and other risks discussed in CareDx’s
filings with the SEC, including the Annual Report on Form 10-K for
the fiscal year ended December 31, 2023 filed by CareDx with the
SEC on February 28, 2024, and other reports that CareDx has filed
with the SEC. Any of these may cause CareDx’s actual results,
performance, or achievements to differ materially and adversely
from those anticipated or implied by CareDx’s forward-looking
statements. CareDx expressly disclaims any obligation, except as
required by law, or undertaking to update or revise any such
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240311505239/en/
CareDx, Inc. Media Relations Anna Czene 818-731-2203
aczene@caredx.com
Investor Relations Greg Chodaczek investor@caredx.com
CareDx (NASDAQ:CDNA)
Historical Stock Chart
From Apr 2024 to May 2024
CareDx (NASDAQ:CDNA)
Historical Stock Chart
From May 2023 to May 2024